The prostate lifestyle trial: PSA changes are not a survival result
A small randomized trial tested comprehensive lifestyle change and measured one-year markers, not long-term survival.

Illustrative food image, not a photograph of the study intervention.
Who actually entered the trial
This trial enrolled 93 volunteers with early, biopsy-proven prostate cancer, serum PSA of 4 to 10 ng/ml, and Gleason scores below 7. All had already chosen not to undergo conventional treatment before recruitment. They were randomly assigned to comprehensive lifestyle changes or usual care. That selection is central, not a detail to skip: the trial was not an invitation for other patients to abandon treatment. It studied a specific group in whom the investigators could compare one-year outcomes without the confounding effects of surgery, radiation, or androgen deprivation therapy at the outset of the trial.
Ornish D, Weidner G, Fair WR, et al.. Journal of Urology 174(3):1065–1069, 2005. PMID 16094059 · DOI
What changed in one year
PSA decreased by 4% in the experimental group and increased by 6% in the usual-care group, with P = 0.016. None of the experimental participants underwent conventional treatment during the reported period, compared with six control participants, who did so because of increased PSA and/or disease progression on magnetic resonance imaging. Those are the outcomes described in the abstract. A PSA percentage change is not a percentage change in mortality or a direct count of cancers cured. The treatment difference is worth reporting, but the trial's short duration and small, selected population limit the conclusions it can support.
Ornish D, Weidner G, Fair WR, et al.. Journal of Urology 174(3):1065–1069, 2005. PMID 16094059 · DOI
The cell result happened in a laboratory
The investigators also exposed LNCaP prostate cancer cells to participants' serum. Cell growth was inhibited by 70% with serum from the experimental group versus 9% with control-group serum, a difference reported as almost eightfold (P < 0.001). This was a laboratory assay using a prostate cancer cell line. It does not mean tumors inside participants shrank by 70%, nor that their survival improved eightfold. The abstract reported that changes in PSA and cell growth were associated with the degree of diet and lifestyle change. Those associations do not identify which individual component produced the result.
Ornish D, Weidner G, Fair WR, et al.. Journal of Urology 174(3):1065–1069, 2005. PMID 16094059 · DOI
A lifestyle package is not a bean trial
The intervention is relevant to discussion of plant-centered lifestyles, but the fetched abstract describes comprehensive lifestyle changes rather than isolating a particular food or providing a complete dietary protocol. This article therefore cannot attribute the PSA result to beans, broccoli, absence of extracted fats, or any single menu rule. The linked bean-and-millet supper is a culinary accompaniment, not a reconstruction of the tested intervention. The authors said intensive lifestyle changes may affect early, low-grade prostate cancer progression and explicitly called for further studies and longer follow-up. That cautious conclusion is stronger science than turning a one-year marker trial into a treatment substitute.
Ornish D, Weidner G, Fair WR, et al.. Journal of Urology 174(3):1065–1069, 2005. PMID 16094059 · DOI